Physicians' Academy for Cardiovascular Education

Novel endovascular baroreflex-amplifying implant lowers BP in therapy-resistant hypertension

Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study

Literature - Spiering W, Williams B, Van der Heyden J, et al., CALM-FIM_EUR investigators - Lancet. 2017 Sep 1. doi: 10.1016/S0140-6736(17)32337-1

Main results

Conclusion

This first-in-man study of a novel endovascular baroreflex amplification device resulted in clinically important reductions in office and 24hrs ambulatory BP with acceptable safety, in patients with resistant hypertension. Most patients needed fewer medications after 6 months of follow-up.

This study has limitations inherent to a small, non-blinded set up, thus the safety profile and efficacy of the Mobius HD needs to be studied further in larger studies with longer follow-up.

References

Show references

Find this article online at The Lancet

Share this page with your colleagues and friends: